Beyond traditional HER2 or FOXA1-targeted therapies, ADC drugs such as RC48 could offer significant benefits to lung cancer patients and potentially transform the future treatment paradigm for lung cancer. This evidence concerns the gene ERBB2 and lung carcinoma.